Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12058
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lau, David K | en |
dc.contributor.author | Andrews, Miles C | en |
dc.contributor.author | Turner, Natalie | en |
dc.contributor.author | Azad, Arun A | en |
dc.contributor.author | Davis, Ian D | en |
dc.contributor.author | Cebon, Jonathan S | en |
dc.date.accessioned | 2015-05-16T01:42:13Z | |
dc.date.available | 2015-05-16T01:42:13Z | |
dc.date.issued | 2014-04-01 | en |
dc.identifier.citation | Melanoma Research; 24(2): 144-9 | en |
dc.identifier.govdoc | 24463460 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12058 | en |
dc.description.abstract | We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)≥2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16%) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes. | en |
dc.language.iso | en | en |
dc.subject.other | Adult | en |
dc.subject.other | Aged | en |
dc.subject.other | Aged, 80 and over | en |
dc.subject.other | Antineoplastic Agents.adverse effects.therapeutic use | en |
dc.subject.other | Disease-Free Survival | en |
dc.subject.other | Female | en |
dc.subject.other | Humans | en |
dc.subject.other | Imidazoles.adverse effects.therapeutic use | en |
dc.subject.other | Male | en |
dc.subject.other | Melanoma.drug therapy.pathology | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Neoplasm Staging | en |
dc.subject.other | Oximes.adverse effects.therapeutic use | en |
dc.subject.other | Prognosis | en |
dc.subject.other | Retrospective Studies | en |
dc.subject.other | Skin Neoplasms.drug therapy.pathology | en |
dc.subject.other | Treatment Outcome | en |
dc.title | A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Melanoma research | en |
dc.identifier.affiliation | aLudwig Institute for Cancer Research - Austin Branch, Joint Ludwig-Austin Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Health bEastern Health Clinical School, Monash University, Victoria, Australia | en |
dc.identifier.doi | 10.1097/CMR.0000000000000036 | en |
dc.description.pages | 144-9 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24463460 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Cebon, Jonathan S | |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.